Dermatology Collaboration and Licensing Deals 2016-2024


Dermatology Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Publication date
April 2024
Number of pages
Product type
Research report
Report edition

Dermatology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the dermatology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of dermatology deals from 2016 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of dermatology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in dermatology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the dermatology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in dermatology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of dermatology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of dermatology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in dermatology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Key benefits

Dermatology Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse dermatology collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time


Report scope

Dermatology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of dermatology trends and structure of deals entered into by leading biopharma companies worldwide.

Dermatology Collaboration and Licensing Deals includes:

  • Trends in dermatology dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of dermatology deal records covering pharmaceutical and biotechnology
  • The leading dermatology deals by value
  • Most active dermatology licensing dealmakers

In Dermatology Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Dermatology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Dermatology Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse dermatology collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in dermatology dealmaking


2.1. Introduction

2.2. Dermatology partnering over the years     

2.3. Dermatology partnering by deal type

2.4. Dermatology partnering by industry sector

2.5. Dermatology partnering by stage of development

2.6. Dermatology partnering by technology type

2.7. Dermatology partnering by therapeutic indication


Chapter 3 – Financial deal terms for dermatology partnering


3.1. Introduction

3.2. Disclosed financials terms for dermatology partnering

3.3. Dermatology partnering headline values

3.4. Dermatology deal upfront payments

3.5. Dermatology deal milestone payments

3.6. Dermatology royalty rates


Chapter 4 – Leading dermatology deals and dealmakers


4.1. Introduction

4.2. Most active in dermatology partnering

4.3. List of most active dealmakers in dermatology    

4.4. Top dermatology deals by value


Chapter 5 – Dermatology contract document directory


5.1. Introduction

5.2. Dermatology partnering deals where contract document available


Chapter 6 – Dermatology dealmaking by therapeutic target


6.1. Introduction

6.2. Deals by dermatology therapeutic target


Deal directory


Deal directory – Dermatology deals by company A-Z 2016 to 2024

Deal directory – Dermatology deals by technology type 2016 to 2024


Deal type definitions


About Biopharma Research Ltd


Current Partnering

Current Agreements

Recent report titles from Current Partnering


Table of figures


Figure 1: Dermatology partnering since 2016

Figure 2: Dermatology partnering by deal type since 2016

Figure 3: Dermatology partnering by industry sector since 2016

Figure 4: Dermatology partnering by stage of development since 2016

Figure 5: Dermatology partnering by technology type since 2016

Figure 6: Dermatology partnering by indication since 2016

Figure 7: Dermatology deals with a headline value

Figure 8: Dermatology deals with upfront payment values

Figure 9: Dermatology deals with milestone payment

Figure 10: Dermatology deals with royalty rates

Figure 11: Active dermatology dealmaking activity since 2016

Figure 12: Top dermatology deals by value since 2016


Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

3Derm Systems, 3M, 23andMe, Abbvie, Ablexis, AbSci, Aclaris Therapeutics, Adalvo, Adaptive Phage Therapeutics, Adhesys Medical, Advanced Human Imaging, Advanced Medical Solutions, Advanz Pharma, Advonex, AFT Pharmaceuticals, AiCuris, AimedBio, Akaal Pharma, Aldena Therapeutics, Alibaba Health, AlivaMab Discovery Services, Allergan, Allergan Aesthetics, Almirall, Alvotech, American Skin Association, Amgen, Amicus Therapeutics, Amor (Suzhou) Medical Sci-Tech, Amyris, Amytrx Therapeutics, ANANDA Scientific, AnGes MG, Anhalt University of Applied Sciences, Animal Allergy Clinical Laboratories, Antibe Therapeutics, AOBiome Therapeutics, Aphex BioCleanse Systems, Applied Biology, APR Applied Pharma Research, Aquavit Pharmaceuticals, Arch Biopartners, Arctic Therapeutics, Arcutis Biotherapeutics, argenx, Armis Biopharma, Arrevus, Arrien Pharmaceuticals, Asia Green Biotechnology, Aslan Pharma, AstraZeneca, Astria Therapeutics, Athenex, Atropos Therapeutics, Aucta Pharmaceuticals, Aurealis Therapeutics, Avaria Health & Beauty, Avicanna, AVIR Pharma, Avita Therapeutics, Azitra, Back-A-Line, BASF, Basilea Pharmaceutica, Bausch & Lomb, Bayer, Beckman Research Institute of City of Hope,, Ben-Gurion University, BGN Technologies, Bill and Melinda Gates Foundation, BinnoPharm, Bio-Gate, Biocogent, Biocon, BioCryst Pharmaceuticals, BioDerm, Biogen, Biohaven Pharmaceuticals, BioLab Sciences, Biolojic Design, Biomedical Advanced Research and Development Authority, BIOMEDX Group, BioMed X Innovation Center, Biomillenia, BiomX, BiondVax, Bioniz Therapeutics, Bionpharma, BioPep, Biophage Pharma, BiopharmX, Bioqube Ventures, BiosanaPharma, Biosolution, BirchBioMed, Bodor Laboratories, Boehringer Ingelheim, Boragen, Boston Pharmaceuticals, Botanix Pharmaceuticals, BoyaLife, Brickell Biotech, Brigham and Women's Hospital, Bright Future Pharmaceutical Lab, Bristol-Myers Squibb, Brown University, Cadila Pharmaceuticals, Can-Fite BioPharma, Candela, CannaSkin, Cannassure Therapeutics, CanniMed Therapeutics, Canopy Growth, Cap Alter Pharma, Cara Therapeutics, CARB-X, Cardiome Pharma, Carestream Health, Cassiopea, Celgene, CellMark Medical, Cell Mogrify, Certara, Ceva Sante Animale, Chelexa Biosciences, Chemstar, Children's Hospital Boston, China Medical System, Chongqing Jingdong Pharmaceutical, Chugai Pharmaceutical, Cipher Pharmaceuticals, Cipla, CIVCO Radiotherapy, Clarify Medical, CMS Aesthetics, CMS Medical, Codex Beauty, Collplant, Columbia University Medical Center, ConvaTec, Cook Biotech, Cosmofix, Cosmo Pharmaceuticals, Crescita Therapeutics, Cronos Group, Crown Laboratories, Cumberland Pharmaceuticals, CURE Pharmaceutical, Cutanea Life Sciences, Cutia Therapeutics, Cynata Therapeutics, CytoSorbents, Dabur, Dalhousie University, Dechra Pharmaceuticals, Defense Health Agency (US), Defense Threat Reduction Agency, Denali Therapeutics, Department of Defense, Department of Veterans Affairs, Dermala, DermapenWorld, Dermavant Sciences, Dermelix Biotherapeutics, Dermira, DermTech, Devonian Health Group, DKSH, Dong-A ST, Dow Pharmaceutical Sciences, Dr. Denese SkinScience, Dr. Reddy's Laboratories, Dr. U Devices, Draper Laboratories, Dr Bragi Company, Dr Kerklaan Therapeutics, DS Biopharma, Dyamed Biotech, Dynasil, EB Research Foundation, EB Research Partnership, Edesa Biotech, Egis, Eirion Therapeutics, Eisai, eKare, Elektrofi, Elevai Labs, Eligo Bioscience, Eli Lilly, Eloxx Pharmaceuticals, Emmaus Life Sciences, Emollivet, Empa, Emphysys, Encore Dermatology, Endo International, Enteris Biopharma, Enzymatica, Epicore Biosystems, EPI Health, epitoMAP, Equillium, Er-Kim, EspeRare Foundation, Estee Lauder, eTheRNA immunotherapies, Eurofins Scientific, European Wellness Biomedical Group, Eve & Co, Evolve BioSystems, Evommune, Evotec, Ewopharma, Excelra, Exicure, Fagron, Felix Biotechnology, Fesarius Therapeutics, Fission Labs LATAM, Flowerkist, Foamix Pharmaceuticals, Fosun Pharmaceutical, Fresh Tracks Therapeutics, Fujifilm Kyowa Kirin Biologics, Fuji Pharma, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Galapagos, Galderma, Geisel School of Medicine at Dartmouth, Gene Biotherapeutics, Genentech, George Washington University, Ginkgo BioWorks, Givaudan, Glenmark Pharmaceuticals, GPC Systems, Grunenthal, GSK, Guangzhou Xiangxue Pharmaceutical, Hairmore Group, Hangzhou Zhongmei Huadong Pharmaceutical, Happify Health, Harvard Medical School, Hawkeye Therapeutics, Healiant, Helsinn Healthcare, Heumann Pharma Generics, High Beauty, Hill Dermaceuticals, Histogen, HitGen, Hope Medicine, Hoth Therapeutics, Houston Methodist Research Institute, HTDK Group, Huapont Pharma, Hume Supernatural, Huons, Hyloris Pharmaceuticals, Hyphens, Iagnosis, Icahn School of Medicine at Mount Sinai, Ice + Jam, Ichnos Sciences, IDEAYA Biosciences, Imbed Bio, IME Medical Electrospinning, IMIDomics, Immunomic Therapeutics, Incyte, Induce Biologics, Innate Biologics, Innosuisse, Innovate UK, Innovative Cellular Therapeutics, Innovent Biologics, Innovize, Inova Diagnostics, Intas Pharmaceuticals, Integra LifeSciences, International Hyperhidrosis Society, Intralytix, Ionis Pharmaceuticals, IQVIA, Isoprene Pharmaceuticals, Jackson Laboratory, James Cook University, Janssen Biotech, Janssen Research & Development, Janssen Therapeutics, Japan Tobacco, JCR Pharmaceuticals, Jiangsu Hengrui Medicine, Jiangsu QYuns Therapeutics, Joerns Healthcare, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, Journey Medical, Juntendo University, Jupiter Wellness, Juyou Biotechnology, JW Pharmaceutical, Kaken Pharmaceutical, Kaleido Biosciences, Kane Biotech, Kashiv BioSciences, Keck School of Medicine of USC, Kent Imaging, Keraderm, Kerecis, King's College Hospital, Kiniksa Pharmaceuticals, KiOmed Pharma, KNOW Bio, Kubota Vision, Kuria Therapeutics, Kyocera, Kyowa Hakko Kirin, L'Oreal, Lannett, Laser Lab Corp, Leon-nanodrugs, LEO Pharma, LGC, LifeMax Laboratories, Ligand Pharmaceuticals, Lighthouse Strategies, Lipidor, LipoTrue, Loreal, Lubrizol, Lupin, Luqa Pharmaceuticals, Lygos, Lysando, Mabwell Bioscience, MainPointe, Mallinckrodt Pharmaceuticals, Mamba Instruments, Maruho, Massachusetts General Hospital, MatriSys Bioscience, Max-Planck, Mayo Clinic, MC2 Therapeutics, McMaster University, Meabco, Medimetriks, MediPharm Labs, MediWound, MedPharm, MedShape, Medshift, Meiji Seika, MEME, Menlo Therapeutics, Merakris Therapeutics, Merck KGaA, Merz, Mesoblast, Metalabs, Metrion Biosciences, Michal Morrison, Michelson Diagnostic, Micreos, Microbio Shanghai, MiMedx, MiNDERA, miraDry, Miravo Healthcare, Mitsubishi Tanabe Pharma, Moberg Pharma, MolecuLight, Molnlycke Health Care, Momenta Pharmaceuticals, Monash University, MoonLake Immunotherapeutics, MorphoSys, Moss Genomics, MT.DERM, MTF Biologics, Mundipharma, MyBiotics Pharma, Mylan Pharmaceuticals, Nabriva Therapeutics, NanoVibronix, National Eczema Association, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, National Psoriasis Foundation, National Research Council Canada, National Research Council of Canada, National Science Foundation, New York University School of Medicine, Nielsen BioSciences, Nogra Pharma, Nordic Pharma Group, North Carolina State University, Northwestern University, Novan, Novan Therapeutics, Novartis, Novelty Nobility, Novo Nordisk, Now Biopharma, Nuevolution, Nuo Therapeutics, Nuvothera, Oakrum Pharma, Oklahoma Medical Research Foundation, Olaregen Therapeutix, OliX Pharmaceuticals, Oneness Biotech, OptiBiotix, Or-Genix Therapeutics, Organogenesis, Organ Technologies, ORIG3N, Orphan Europe, Orpharm, Otsuka, Ovation Science, OWC Pharmaceutical Research, Paladin Labs, Palisade Bio, Palvella Therapeutics, Paradigm Therapeutics, Paratek Pharmaceuticals, Patagonia Pharmaceuticals, Patient-Centered Outcomes Research Institute, PCG Clinical Services, Pediatric Dermatology Research Alliance, Pediatrix Therapeutics, PellePharm, Pelle Ventures, Perrigo, Pfizer, PharmaResearch Products, Phosphagenics, Pierre Fabre, Pierre Fabre Dermatologie, Pint Pharma, Piqur Therapeutics, Pixie Dust Technologies, Popit, Portola Pharmaceuticals, Precisio Biotix Therapeutics, Pressure BioSciences, Priovant Therapeutics, Promius Pharma, Promore Pharma, Proscia, Protagen, Protagonist Therapeutics, Proteic Bioscience, Proya Cosmetics, Purdue Pharma, Purnovate, Pyramid Biosciences, Queensland University of Technology, Quoin Pharmaceuticals, Rational Surgical Solutions, Realm Therapeutics, Recludix Pharma, Regenerative Biologics, Regenerative Medicine of Latin America, Regranion, ReLeaf Europe, Relife, Renovacare, Repertoire Immune Medicines, Replicel Life Sciences, Repurpose.AI, Resilia Pharmaceuticals, Restorix Health, Revision Skincare, RIKEN Yokohama Institute Omics Science Center, Rochal Industries, Roche, Rodan and Fields, Roivant Sciences, RVL Pharmaceuticals, Samsung Bioepis, Samsung Biologics, Samumed, Sandoz, Sanmina, Sanofi, Sanpellegrino Cosmetics, Sanuwave Health, SastoMed, Sato Pharmaceutical, SciBase, Science 37, Sciton, Scohia Pharma, Searchlight Pharma, Second Genome, Sensus Healthcare, SenzaGen, Seqirus, Sequence Bio, Sequential Skin, SerenaGroup, Shanghai Haohai Biological Technology, SHL Medical, Signum Biosciences, Simcere Pharmaceuticals, Simris Biomimetics, Sinclair Pharmaceuticals, Sinovant Sciences, Sirenas, Sirona Biochem, Skin and Cancer Institute, SkinBiotix, SkinSciPac, Skinvisible, Sofwave Medical, Sol-Gel, Soliton, Sonoma Pharmaceuticals, Sosei Heptares, StemCell Systems, Stratpharma, Sumitomo Chemical Company, Sun Pharmaceutical, SutroVax, Suzhou Connect Biopharmaceuticals, Swiss Institute of Allergy and Asthma Research, Swysh, Taiho, Takeda Pharmaceutical, Tauriga Sciences, Technion Research and Development Foundation, TekCyte, Telemedicine Solutions, Teva Pharmaceutical Industries, Teva Pharmaceuticals USA, TheraVida, Thomas Jefferson University, Thought Leadership & Innovation Foundation, Timber Pharmaceuticals, Tissue Analytics, Tohoku University, Torii Pharmaceutical, Triage Technologies, Turn Therapeutics, TWi Biotechnology, Tyris Therapeutics, uBiome, Uni-Bio Science, UNION Therapeutics, University Gottingen, University of Alabama at Birmingham, University of Barcelona, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Los Angeles, University of California San Francisco, University of Cincinnati, University of Colorado, University of Colorado Denver, University of Dundee, University of Manchester, University of Maryland Baltimore, University of Massachusetts, University of New Mexico, University of North Carolina, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of South Australia, University of Virginia, University of Washington, University of Wisconsin, US Army, US Army Medical Research and Material Command, Valeant Pharmaceuticals, ValenzaBio, Vanderbilt University, Vasomune Therapeutics, Vaxcyte, Venturis Therapeutics, Vericel, Verily, Verrica Pharmaceuticals, ViaDerma, Vial, Victoria University, Vifor Pharma, Vipergen, VisionQuest Biomedical, Visualant, VisualDx, Vitro Biopharma, Vitruvias Therapeutics, Vizient, Voronoi, Wearifi, Weill Cornell Medical College, Winhealth Pharma Group, Wistar Institute, Worcester Polytechnic Institute (WPI), Worldwide Clinical Trials, WuXi Biologics, X-chem, Xbiome, Xcede Technologies, Xycrobe Therapeutics, Xylyx Bio, Yale School of Medicine, YOFOTO (China) Health Industry, ZappRx, Zenoaq, Zentiva, Zenyaku Kogyo, Zhittya Genesis Medicine, Zuellig Pharma China, Zymeworks

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.